LIPID HOMEOSTASIS PECULARITIES IN ISCHEMIC HEART DISEASE PATIENTS WITH HEART FAILURE SYMPTOMS, DIABETES MELLITUS 2 TYPE AND METABOLIC SYNDROME DEPENDING ON MEDICATION PECULIARITIES

  • E.I. Zalyubovskaya
Keywords: ischemic heart disease, heart failure, diabetes mellitus, metabolic syndrome, ACE inhibitors, β-blockers, general cholesterol, lipoproteids of low density, lipoproteids of very low density, lipoproteids of high density, atherogeneity

Abstract

91 patients have been examined to study the effectiveness of (ACE inhibitor) lysinoprile in various dosesincluding its combination with carvedilol β-blocker as a complex treatment in ischemic heart disease patients with hert failure symptoms, diabetes mellitus 2 type (D) and metabolic syndrome (MS).

The conclusion has been made that doses of lysinopril and carvedilol as a complex therapy in ischemic heart disease patients with hert failure symptoms, diabetes mellitus 2 type (D) and metabolic syndrome (MS) has a definitely positive effect concerning normalization of general cholesterol level (CH), triglycerids (TG), cholesterol lipoproteid of low density (CH-LPLD). Increasing lysinoprile dose allows to improve the level of CH-LPLD and lipoproteids of very low density (CH-LPVLD), and carvedilol promotes the reduction of CH, TG, CH-LPLD, CH -LPVLD levels. Combination of lysinoprile 2,5-5,0 mg with carvedilol 37,5-50,0 mg permits to increase the level of CH lipoproteids of high density.

Downloads

Download data is not yet available.

References

1. Тучинська М.А. Дозозалежний вплив інгібіторів АПФ та бета-блокаторів на функцію ендотелію та процеси ремоделювання міокарда у хворих, що перенесли інфаркт міокарда: Автореф. дис. ... канд. мед. наук: 14.01.11 / Харківський Державний медичний університет. - Харків. - 2004. - 20 с.

2. Pyorala R., De Backer G., Graham J. // Europ. Heart J. - 1994. - Vol. 15. - № 1. - Р. 1300-1331.

3. WHO Report: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: report of а WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. - 1999. - 27 р.

4. Чаяло П.П. Нарушения обмена липопротеидов. -К:Здоров’я. - 1990. - 184 с.

5. Гланц С. Медикобиологическая статистика / Пер. с англ. -М.:Практика. - 1998. - 459с.
How to Cite
Zalyubovskaya, E. (1). LIPID HOMEOSTASIS PECULARITIES IN ISCHEMIC HEART DISEASE PATIENTS WITH HEART FAILURE SYMPTOMS, DIABETES MELLITUS 2 TYPE AND METABOLIC SYNDROME DEPENDING ON MEDICATION PECULIARITIES. The Journal of V. N. Karazin Kharkiv National University, Series "Medicine", (15), 79-84. Retrieved from https://periodicals.karazin.ua/medicine/article/view/7013
Section
Clinical research